Freenome (FRNM) vs Fortrea (FTRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Fortrea (FTRE) has outperformed Freenome (FRNM) over the past year, gaining 93.9% versus a gain of 48.9%. Fortrea is the larger company by market cap ($1.98 billion vs $1.70 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FRNM | FTRE |
|---|---|---|
| Share price | $15.78 | $20.84 |
| Market cap | $1.70B | $1.98B |
| 1-day change | -0.19% | +2.31% |
| YTD return | +21.11% | +20.81% |
| 1-year return | +48.87% | +93.86% |
| Forward P/E | — | 18.49 |
| EPS (TTM) | $-2.04 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.72B |
| Revenue growth (YoY) | — | +1.00% |
| Net income (latest FY) | $837.47K | $-986.20M |
| Gross margin | — | 18.50% |
| Operating margin | — | -32.04% |
| Net margin | — | -36.21% |
| 52-week high | $17.50 | $23.51 |
| 52-week low | $9.95 | $8.55 |
| Distance from 52-week high | -9.83% | -11.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +14.07% | -0.05% |
| Average volume | 802.26K | 1.49M |
| Shares outstanding | 107.45M | 95.10M |
| Employees | 375 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTRE has outperformed FRNM by 45.0 percentage points over the past year.
About Freenome
FRNM stock →Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer.
Health Care · Medical Specialities · 375 employees
About Fortrea
FTRE stock →Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Health Care · Medical Specialities · 14,000 employees
FRNM vs FTRE FAQ
Which is bigger, Freenome or Fortrea?
Fortrea (FTRE) is larger, with a market capitalization of $1.98B compared with $1.70B for Freenome (FRNM).
Which stock has performed better over the past year, FRNM or FTRE?
FTRE returned +93.86% over the past 12 months, compared with +48.87% for FRNM (price return, excluding dividends). Past performance does not predict future results.
Are Freenome and Fortrea in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.